Home β€Ί Stock analysis β€Ί NCNA

NuCana (NCNA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

NCNA dips 2.9% to $0.99, a 52-week low, 7 down days in a row. Closed at $0.99, -2.93% vs the prior close of $1.02. Day range $0.97–$1.03, opened at $1.02.

Last close$0.99-2.93%
Day range0.97–1.03
Open1.02
Volume46.27K
52-week range0.95–5.65
Avg volume (20d)254.38K

NCNA daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” NCNA dips 2.9% to $0.99, a 52-week low, 7 down days in a row
Oct 15, 2026 β€” NCNA dips 2.9% to $1.02, a 52-week low, 6 down days in a row
Oct 14, 2026 β€” NCNA ends flat (+0.0%) to $1.05, 5 down days in a row
Oct 13, 2026 β€” NCNA dips 2.8% to $1.05, a 52-week low, 4 down days in a row
Oct 12, 2026 β€” NCNA dips 1.8% to $1.08, 3 down days in a row
Oct 9, 2026 β€” NCNA dips 2.7% to $1.10
Oct 8, 2026 β€” NCNA dips 0.9% to $1.13
Oct 7, 2026 β€” NCNA jumps 4.6% to $1.14
Oct 6, 2026 β€” NCNA rises 2.8% to $1.09
Oct 5, 2026 β€” NCNA dips 2.8% to $1.06, a 52-week low, 3 down days in a row
Oct 2, 2026 β€” NCNA slides 6.8% to $1.09, a 52-week low on 2.4x normal volume

NCNA latest news & SEC filings

Every SEC filing by or about NCNA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Sep 30, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001193125-26-408365

Aug 13, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001193125-26-349254

Jun 24, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001193125-26-280239

Jun 23, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001193125-26-279925

Things to know before you trade NCNA

NCNA market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 20261.021.030.970.9946.27K
Oct 15, 20261.021.040.971.0255.10K
Oct 14, 20261.051.071.031.0538.00K
Oct 13, 20261.101.101.051.0552.00K
Oct 12, 20261.101.141.081.0828.60K
Oct 9, 20261.131.181.071.1067.40K
Oct 8, 20261.141.141.101.1334.60K
Oct 7, 20261.111.181.061.1451.00K
Oct 6, 20261.081.141.051.0950.90K
Oct 5, 20261.121.121.031.0670.30K
Oct 2, 20261.181.220.951.09320.90K
Oct 1, 20261.291.311.011.17799.10K
Sep 30, 20261.291.441.261.353.30M
Sep 29, 20261.291.291.211.2124.70K
Sep 28, 20261.321.371.261.2923.60K
Sep 25, 20261.301.351.211.2838.20K
Sep 24, 20261.311.341.271.329.20K
Sep 23, 20261.331.351.301.3127.80K
Sep 22, 20261.351.381.301.3320.40K
Sep 21, 20261.351.391.321.3225.30K

About NuCana

NuCana (NCNA) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in EDINBURGH, United Kingdom. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1709626.

NCNA board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Hugh GriffithChief Executive OfficerMar 18, 2026
Andrew Martin KayDirectorMar 18, 2026
Cyrille LeperlierDirectorMar 18, 2026
Elliott M. LevyDirectorJun 24, 2026
Martin C.B. MellishDirectorMar 20, 2026

Executive officers

NameTitleLatest filing
Jeffrey D. BlossChief Medical OfficerJun 23, 2026
Theresa Margaret Ms BruceChief Operating OfficerApr 16, 2026
Hugh GriffithChief Executive OfficerMar 18, 2026
David James HarrisonHead of Translational MedicineMar 24, 2026
Ian Alexander WebsterSee RemarksMar 18, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

NCNA financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
No annual XBRL figures available (foreign filers often report on Form 20-F).

Latest balance sheet: total assets $β€”, total liabilities $β€”, cash $β€”.

NCNA earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on NCNA

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.